Answers are grounded in this paper and cite their sources.
To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.
No takes yet. Share an insight, caveat, or question.
Fleischmann et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: